Skip to content
MARKETS / NASDAQ / STEX
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Streamex Corp. STEX

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$-462.8M
In brief

What this company does

The Company's principal business is tokenized finance and real-world asset digitization, conducted through Streamex, and it also retains a legacy healthcare technology innovation focused on advanced signal acquisition and analysis through its PURE EP platform. The Company has launched a tokenized gold product called GLDY, which provides investors with a digital token representing fractional interests in a special purpose vehicle domiciled in the Cayman Islands that holds physical gold and participates in a gold leasing program. Each GLDY Token corresponds to one troy ounce of gold held by the SPV, with yield features generated through gold leasing activities administered through a Tokenized Yield Partnership Agreement between the Company and Monetary Metals & Co., a Delaware corporation. As of December 31, 2025, the Company had 6 full-time employees, and additionally used 4 consultants as needed to perform various specialized services.

Written from the business description in Streamex Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.0 · Net income -10.3
-20M-40M2013201520172019202120232025
Compound annual growth
−55.1%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2024 · Operating -32155.0% · Net -25847.5%
-50000%-100000%-150000%2013201520172019202120232025
ROE
FY2025 · ROE -703.1%
-20000%-40000%2013201520172019202120232025

Each USD of equity lost 703 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -17.5
-10M-20M2013201520172019202120232025

Total assetsUSD 187.5M
EquityUSD 133.2M
CashUSD 20.3M
DepositsUSD 19.7M
Current ratio1.68×

Equity funds 71% of total assets.

The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B·0.00.00.00.00.0·······
Operating income $B−0.1−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.1−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B−0.0··0.00.00.00.00.00.00.00.00.00.0
Net income $B−0.5−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B··−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−9.65−0.75−3.95−6.33·−1.87−1.65−1.25−1.25−0.60−0.70−0.91−1.23
Dividend / sh $·············
Payout %·············
ROE %−703.1··−431.0−174.4−294.1−470.7−48736.5·····
Shares out B0.050.020.010.050.040.030.020.020.000.000.000.010.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 54 reconciliationsAUDITED

Reconciled in 13 of 19 fiscal years. 41 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image